High Calibre Additions to the Juvenescence Team

DOUGLAS, Isle of Man--(BUSINESS WIRE)-- Juvenescence Limited, a life sciences company focused on modifying aging and increasing human longevity, is pleased to announce the appointment of Dr. Jean-Christophe Renondin to its Main Board of Directors, and of Dr. David Roblin and Dr. Steve Felstead to its Senior Leadership Team.

Jim Mellon, Chair of Juvenescence, said: “We are delighted to welcome Healthcare Senior Investment Manager and medical practitioner Jean-Christophe Renondin to the Main Board of Juvenescence, representing the State General Reserve Fund (SGRF) of the Sultanate of Oman. Jean-Christophe is a very experienced and respected biotech investor who brings a great deal of both investment and medical knowledge to the Board, as well as a wealth of Middle Eastern contacts, and as such is a very strong addition to the Juvenescence talent bench.”

Dr. Greg Bailey, CEO of Juvenescence, said: “We are very fortunate to have been able to attract David Roblin and Steve Felstead with their extensive backgrounds in drug development to a company at our stage of development. David has joined us as the Chief Operating Officer of the parent Corporation and CEO of the pharmaceutical division. He was the Head of European R&D at Pfizer and recently the Chair of Scientific Translation at the Frances Crick Institute. Steve was the Head of Clinical Research Pharmatherapeutics Division at Pfizer and has joined us as Head of Development Projects. David and Steve bring a wealth of experience in drug development along with an ability to manage a very sophisticated and diverse team as Juvenescence focusses on taking our ten pharmaceutical programs into human trials.”

About Juvenescence Ltd:

Juvenescence Limited is a life sciences company developing therapies to modify aging and increase healthy human longevity. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005727/en/